LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 14

Suchoptionen

  1. Artikel: Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk

    Mazza, Alberto / Nicoletti, Mariaceleste / Lenti, Salvatore / Torin, Gioia / Rigatelli, Gianluca / Pellizzato, Marzia / Fratter, Andrea

    Journal of medicinal food. 2020 May 22,

    2020  

    Abstract: The effectiveness of statins in the primary and secondary prevention of cardiovascular (CV) diseases has been widely proven. However, the onset of adverse events associated with their use prevents to achieve the therapeutic targets recommended by the ... ...

    Abstract The effectiveness of statins in the primary and secondary prevention of cardiovascular (CV) diseases has been widely proven. However, the onset of adverse events associated with their use prevents to achieve the therapeutic targets recommended by the guidelines (GL) for the management of dyslipidemia. In the event of statin intolerance, the GL recommend to use bile acid sequestrants, fibrates, and ezetimibe in monotherapy, but their benefits in improving lipid pattern are quite modest. This study aims at evaluating the effectiveness and safety of a nutraceutical compound (NC) associated with ezetimibe (EZE) on the lipid profile in statin-intolerant patients with moderate-to-high CV risk. Ninety-six statin-intolerant hypertensive and hypercholesterolemic subjects treated pharmacologically with EZE 10 mg daily were randomized in open label (n = 48) to take for 3 months a NC containing Monacolin-K (MK), Berberine Hydrochloride (BC), t-Resveratrol (RES), Quercetin (QUER), and Chromium (CH) in the form of a gastro-resistant tablet that improves enteric bioaccessibility and bioavailability of these substances. The control group (n = 48) took only EZE in monotherapy at the same dosage; both groups followed a standardized lipid-lowering diet. The total serum cholesterol (TC), low density lipoprotein cholesterol (LDLC), high density lipoprotein cholesterol (HDLC), triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine phosphokinase (CPK) levels were compared at the follow-up in both groups using Student's t-test. TC and LDL levels reduced in both groups, but were lower in the group treated with EZE + NC (−25.9% vs. −15%, P < .05 and −38.7% vs. −21.0%, P < .05, respectively). No changes were observed in either group regarding a decrease in TG (−9.4% vs. −11.7%, NS) and an increase in HDLC (+4.2% vs. +1.1%, NS). The AST, ALT, and CPK levels increased in the group treated with the EZE + NC compared to the control group, but were still within the acceptable range. There was no difference concerning the lipid-lowering treatment between gender, and no patient withdrew from the study. In the short term, the EZE + NC combination therapy is well tolerated and effective in improving TC and LDLC levels in statin-intolerant patients with moderate-to-high CV risk.
    Schlagwörter alanine transaminase ; aspartate transaminase ; berberine ; bile acids ; bioavailability ; blood serum ; chromium ; creatinine ; dietary supplements ; gender ; high density lipoprotein cholesterol ; hypercholesterolemia ; lipid composition ; lovastatin ; low density lipoprotein cholesterol ; patients ; quercetin ; resveratrol ; risk ; t-test ; therapeutics ; triacylglycerols
    Sprache Englisch
    Erscheinungsverlauf 2020-0522
    Erscheinungsort Mary Ann Liebert, Inc.
    Dokumenttyp Artikel
    ZDB-ID 1427365-2
    ISSN 1557-7600 ; 1096-620X
    ISSN (online) 1557-7600
    ISSN 1096-620X
    DOI 10.1089/jmf.2020.0019
    Datenquelle NAL Katalog (AGRICOLA)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5916: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension.

    Mazza, Alberto / Schiavon, Laura / Rigatelli, Gianluca / Torin, Gioia / Lenti, Salvatore

    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension

    2019  Band 26, Heft 4, Seite(n) 345–350

    Abstract: Introducion: Treatment strategies for patients with pre-hypertension and low-moderate cardiovascular (CV) risk may include nutraceutical compounds (NCs).: Aim: To investigate the efficacy and safety of a new-generation of NC in lowering BP values and ...

    Abstract Introducion: Treatment strategies for patients with pre-hypertension and low-moderate cardiovascular (CV) risk may include nutraceutical compounds (NCs).
    Aim: To investigate the efficacy and safety of a new-generation of NC in lowering BP values and improving metabolic profile, in a group of hyper-cholesterolemic subjects with pre-hypertension.
    Methods: 131 subjects with pre-hypertension (systolic BP 130-139 mmHg and/or diastolic BP 85-89 mmHg) without organ damage and history of CV diseases were enrolled. 66 subjects were treated with a once-daily oral formulation of a NC (red yeast rice, Berberine, Coenzyme Q10, folic acid and chrome) added to diet for 3 months, while 65 patients followed a diet only. Differences in serum total cholesterol (TC), low- and high-density lipoprotein cholesterol (LDLC and HDLC), triglycerides (TG), glycemia, creatine phosphokinase (CPK), aspartate aminotransferase (AST) alanine aminotransferase (ALT) and body mass index (BMI) were evaluated.
    Results: At the end of treatment, significant reductions of TC, LDLC, TG glucose levels were observed in both treatment groups, while HDLC values increased in the active treatment group only. A greater reduction of TC, LDLC and glycemia was observed in the treatment group. TG levels were not different within the two groups. BP and BMI levels remained unchanged, as well AST, ALT; CPK slightly increased in both groups, but it remained in the normal range.
    Conclusions: In patients with pre-hypertension, NC supplementation was safe, well tolerated and effective in improving lipid pattern and glucose levels and in preventing the progression to overt hypertension.
    Mesh-Begriff(e) Aged ; Antihypertensive Agents/adverse effects ; Antihypertensive Agents/therapeutic use ; Biomarkers/blood ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Blood Pressure/drug effects ; Dietary Supplements/adverse effects ; Disease Progression ; Female ; Humans ; Hypercholesterolemia/blood ; Hypercholesterolemia/diagnosis ; Hypercholesterolemia/drug therapy ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/therapeutic use ; Hypolipidemic Agents/adverse effects ; Hypolipidemic Agents/therapeutic use ; Italy ; Lipids/blood ; Male ; Middle Aged ; Prehypertension/diagnosis ; Prehypertension/drug therapy ; Prehypertension/physiopathology ; Prospective Studies ; Time Factors ; Treatment Outcome
    Chemische Substanzen Antihypertensive Agents ; Biomarkers ; Blood Glucose ; Hypoglycemic Agents ; Hypolipidemic Agents ; Lipids
    Sprache Englisch
    Erscheinungsdatum 2019-07-27
    Erscheinungsland New Zealand
    Dokumenttyp Journal Article ; Randomized Controlled Trial
    ZDB-ID 1236337-6
    ISSN 1179-1985 ; 1120-9879
    ISSN (online) 1179-1985
    ISSN 1120-9879
    DOI 10.1007/s40292-019-00332-6
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4289: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk.

    Mazza, Alberto / Nicoletti, Mariaceleste / Lenti, Salvatore / Torin, Gioia / Rigatelli, Gianluca / Pellizzato, Marzia / Fratter, Andrea

    Journal of medicinal food

    2020  Band 24, Heft 1, Seite(n) 59–66

    Abstract: The effectiveness of statins in the primary and secondary prevention of cardiovascular (CV) diseases has been widely proven. However, the onset of adverse events associated with their use prevents to achieve the therapeutic targets recommended by the ... ...

    Abstract The effectiveness of statins in the primary and secondary prevention of cardiovascular (CV) diseases has been widely proven. However, the onset of adverse events associated with their use prevents to achieve the therapeutic targets recommended by the guidelines (GL) for the management of dyslipidemia. In the event of statin intolerance, the GL recommend to use bile acid sequestrants, fibrates, and ezetimibe in monotherapy, but their benefits in improving lipid pattern are quite modest. This study aims at evaluating the effectiveness and safety of a nutraceutical compound (NC) associated with ezetimibe (EZE) on the lipid profile in statin-intolerant patients with moderate-to-high CV risk. Ninety-six statin-intolerant hypertensive and hypercholesterolemic subjects treated pharmacologically with EZE 10 mg daily were randomized in open label (
    Mesh-Begriff(e) Anticholesteremic Agents/therapeutic use ; Cardiovascular Diseases/drug therapy ; Dietary Supplements ; Drug Therapy, Combination ; Ezetimibe/therapeutic use ; Heart Disease Risk Factors ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Lipids/blood ; Risk Factors ; Treatment Outcome
    Chemische Substanzen Anticholesteremic Agents ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Lipids ; Ezetimibe (EOR26LQQ24)
    Sprache Englisch
    Erscheinungsdatum 2020-05-22
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Randomized Controlled Trial
    ZDB-ID 1427365-2
    ISSN 1557-7600 ; 1096-620X
    ISSN (online) 1557-7600
    ISSN 1096-620X
    DOI 10.1089/jmf.2020.0019
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5916: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk.

    Mazza, Alberto / Schiavon, Laura / Rigatelli, Gianluca / Torin, Gioia / Montanaro, Fabio / Lenti, Salvatore

    Food & function

    2018  Band 9, Heft 7, Seite(n) 3845–3852

    Abstract: Background - The clinical hypocholesterolemic effect of nutraceutical compounds (NCs) containing red yeast rice extracts providing a daily dose of 2.5-10 mg of monacolin K is now well established. For this reason, NCs may be a viable alternative to the ... ...

    Abstract Background - The clinical hypocholesterolemic effect of nutraceutical compounds (NCs) containing red yeast rice extracts providing a daily dose of 2.5-10 mg of monacolin K is now well established. For this reason, NCs may be a viable alternative to the statin drugs commonly used to lower cholesterol levels. However, in order to avoid some possible statin-like side effects, most NCs available on the market contain low doses of monacolin K, which could reduce their efficacy. The aim of this study was to investigate the efficacy and safety of a NC containing high doses of monacolin K (10 mg) in improving the lipid profile and glucose metabolism when added to the diet versus the diet alone in a group of hypertensive and hyper-cholesterolemic subjects at low cardiovascular risk. Methods - Thirty subjects with grade-1 essential hypertension (mean age 51.5 ± 7.8 years, 62.9% males) were enrolled in the treatment group (NC group). These subjects followed a programmed diet and took one tablet a day of a NC containing red yeast rice, policosanols, resveratrol and chromium picolinate for 1 month and were compared with an equivalent group of subjects that followed only a diet program. Differences in serum total cholesterol (TC), low-density- and high-density-lipoprotein cholesterol (LDLC and HDLC), triglycerides (TG) and blood glucose between groups were compared by analysis of variance. Results - In both groups, a significant reduction of TC, TG and LDLC was observed. In the treatment group from the baseline to the follow-up the reduction of TC (230.93 ± 28.0 vs. 188.63 ± 18.1, p < 0.001) and LDLC (153.10 ± 22.5 vs. 116.54 ± 17.7, p < 0.001) was significantly greater compared to the control group (differences between treatments = 9.19% and 12.29%, respectively); in addition a significant higher reduction in blood glucose (89.1 ± 7.6 vs. 83.7 ± 4.6, p < 0.001) was also observed (differences between treatments = 4.28%). HDLC levels remained unchanged in both groups. Conclusions - In summary, the NC containing high doses of monacolin K appeared to be safe, well tolerated and effective at improving lipid and glucose patterns.
    Mesh-Begriff(e) Adult ; Biological Products/chemistry ; Blood Glucose/metabolism ; Cardiovascular Diseases/metabolism ; Cardiovascular Diseases/prevention & control ; Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Dietary Supplements/analysis ; Female ; Humans ; Hypercholesterolemia/drug therapy ; Hypercholesterolemia/metabolism ; Hypertension/drug therapy ; Hypertension/metabolism ; Lipids/blood ; Lovastatin/administration & dosage ; Male ; Middle Aged ; Risk Factors ; Time Factors ; Triglycerides/blood
    Chemische Substanzen Biological Products ; Blood Glucose ; Cholesterol, HDL ; Cholesterol, LDL ; Lipids ; Triglycerides ; red yeast rice ; Lovastatin (9LHU78OQFD)
    Sprache Englisch
    Erscheinungsdatum 2018-06-27
    Erscheinungsland England
    Dokumenttyp Journal Article ; Randomized Controlled Trial
    ZDB-ID 2612033-1
    ISSN 2042-650X ; 2042-6496
    ISSN (online) 2042-650X
    ISSN 2042-6496
    DOI 10.1039/c8fo00415c
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Bonn

    Z 7872: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  5. Artikel ; Online: Long-term effect of the perindopril/indapamide/amlodipine single-pill combination on left ventricular hypertrophy in outpatient hypertensive subjects.

    Mazza, Alberto / Townsend, Danyelle M / Schiavon, Laura / Torin, Gioia / Lenti, Salvatore / Rossetti, Ciro / Rigatelli, Gianluca / Rubello, Domenico

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    2019  Band 120, Seite(n) 109539

    Abstract: Background: Most antihypertensive drugs used in monotherapy or in combination therapy reduce the left ventricular mass index (LVMI). However, little is known about the effects on LVMI of a triple fixed-dose combination (TFC) therapy, containing in a ... ...

    Abstract Background: Most antihypertensive drugs used in monotherapy or in combination therapy reduce the left ventricular mass index (LVMI). However, little is known about the effects on LVMI of a triple fixed-dose combination (TFC) therapy, containing in a single pill an angiotensin-converting enzyme inhibitor (ACEI), a diuretic and a calcium channel blocker (CCB).
    Methods: In this prospective open-label study, 92 patients with essential hypertension were randomized to treatment with a TFC of perindopril/indapamide/amlodipine at different doses or a triple free combination therapy (FCT) including ACEI/diuretic/CCB. Office blood pressure (BP) measurement, 24 h-ambulatory BP monitoring and echocardiography were performed at baseline and during a 14-month follow-up. The BP variability (BPV) over 24 h was calculated as ± standard deviation of the daytime systolic BP. Differences between office and monitored BP and LVMI were evaluated by ANOVA for repeated measures.
    Results: A significant BP-lowering effect was observed for both treatments. At follow-up, BPV was reduced in both the treatment groups vs. the baseline (14.0±1.5 vs. 17.0±1.8 and 16.2±2.1 vs. 17.6±2.3, respectively), but it was lower in the TFC vs. the FCT group (14.0±1.5 vs. 16.1±2.2, P < 0.05). LVMI was lower in both the treatment groups, but the change was greater for TFC vs. FCT (-8.3±4.9% vs. -2.0 ±2.1%, P < 0.0001). Left ventricular hypertrophy (LVH) regression was greater in the TFC vs. the FCT group (43.5% vs. 30.4%, P < 0.05).
    Conclusions: Independently of BP values achieved, the antihypertensive TFC therapy was more effective than FCT in LVMI reduction and LVH regression, possibly related to drugs' intrinsic properties and to BPV modulation.
    Mesh-Begriff(e) Amlodipine/therapeutic use ; Blood Pressure/drug effects ; Blood Pressure Monitoring, Ambulatory ; Drug Combinations ; Female ; Follow-Up Studies ; Humans ; Hypertension/complications ; Hypertension/drug therapy ; Hypertension/physiopathology ; Hypertrophy, Left Ventricular/complications ; Hypertrophy, Left Ventricular/drug therapy ; Hypertrophy, Left Ventricular/physiopathology ; Indapamide/therapeutic use ; Male ; Middle Aged ; Outpatients ; Perindopril/therapeutic use ; Systole/drug effects ; Time Factors
    Chemische Substanzen Drug Combinations ; amlodipine, perindopril drug combination ; indapamide, perindopril drug combination ; Amlodipine (1J444QC288) ; Indapamide (F089I0511L) ; Perindopril (Y5GMK36KGY)
    Sprache Englisch
    Erscheinungsdatum 2019-10-15
    Erscheinungsland France
    Dokumenttyp Clinical Trial ; Journal Article
    ZDB-ID 392415-4
    ISSN 1950-6007 ; 0753-3322 ; 0300-0893
    ISSN (online) 1950-6007
    ISSN 0753-3322 ; 0300-0893
    DOI 10.1016/j.biopha.2019.109539
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ud II Zs.198: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Predictive ability of the new 2014 ESC prognostic model in acute pulmonary embolism.

    Masotti, Luca / Panigada, Grazia / Landini, Giancarlo / Pieralli, Filippo / Corradi, Francesco / Lenti, Salvatore / Migliacci, Rino

    International journal of cardiology

    2016  Band 202, Seite(n) 801–803

    Mesh-Begriff(e) Acute Disease ; Biomarkers/analysis ; Cardiology ; Echocardiography ; Europe/epidemiology ; Hemodynamics/physiology ; Humans ; Incidence ; Predictive Value of Tests ; Prognosis ; Pulmonary Embolism/diagnosis ; Pulmonary Embolism/epidemiology ; Pulmonary Embolism/physiopathology ; Societies, Medical ; Survival Rate/trends
    Chemische Substanzen Biomarkers
    Sprache Englisch
    Erscheinungsdatum 2016-01-01
    Erscheinungsland Netherlands
    Dokumenttyp Letter
    ZDB-ID 779519-1
    ISSN 1874-1754 ; 0167-5273
    ISSN (online) 1874-1754
    ISSN 0167-5273
    DOI 10.1016/j.ijcard.2015.10.007
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1673: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome.

    Mazza, Alberto / Lenti, Salvatore / Schiavon, Laura / Di Giacomo, Ezio / Tomasi, Monica / Manunta, Roberto / Torin, Gioia / Townsend, Danyelle M / Rubello, Domenico

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    2018  Band 105, Seite(n) 992–996

    Abstract: Introduction: Metabolic syndrome (MetS) is a world-wide epidemic disease with an increased risk of morbidity and mortality. Treatment strategies of MetS include pharmacologic and non-pharmacologic interventions and in this respect a relevant role has ... ...

    Abstract Introduction: Metabolic syndrome (MetS) is a world-wide epidemic disease with an increased risk of morbidity and mortality. Treatment strategies of MetS include pharmacologic and non-pharmacologic interventions and in this respect a relevant role has been shown for nutraceutical compounds (NCs). The aim of this study was to investigate the efficacy and safety of NCs incorporated with diet and lifestyle management versus diet alone, in lowering blood pressure (BP) values and improving lipid and glucose profile, in a group of hypertensives and hyper-cholesterolemic patients with MetS.
    Methods: 104 subjects with MetS (mean age 57.4 ± 8.8 years, 51% males) without history of cardio-vascular (CV) diseases were enrolled in the study. 52 subjects were treated with a once-daily oral formulation of a NCs containing red yeast rice and coenzyme Q10 added to their diet for 2 months and were compared with the 52 patients following a diet program. Differences in BP, serum total cholesterol (TC), low- and high-density-lipoprotein cholesterol (LDLC and HDLC), triglycerides (TG) and glucose values were compared by analysis of variance.
    Results: A significant reduction of BP, TC, TG, LDLC and glucose levels was observed in both treatment groups. However, a greater reduction of systolic BP (-5.2 vs. -3.0 mmHg), diastolic BP (-4.9 vs. 2.9 mmHg), total cholesterol (-17.2%), LDLC (-21.8%), TG (-16.0%) and serum glucose (-3.4%) was observed in the treatment group relative to the control (p < 0.001 for all); HDLC remained unchanged (p = N.S.). Gender difference was not found in either group (p = N.S.).
    Conclusions: In patients with MetS, NC supplementation was safe, well tolerated and effective in improving clinic BP, lipid and glucose profile.
    Mesh-Begriff(e) Aged ; Anticholesteremic Agents/administration & dosage ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Diet, Mediterranean ; Dietary Supplements ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Hypercholesterolemia/blood ; Hypercholesterolemia/diet therapy ; Hypercholesterolemia/drug therapy ; Hypertension/blood ; Hypertension/diet therapy ; Hypertension/drug therapy ; Lovastatin/administration & dosage ; Male ; Metabolic Syndrome/blood ; Metabolic Syndrome/diet therapy ; Metabolic Syndrome/drug therapy ; Middle Aged ; Treatment Outcome ; Triglycerides/blood ; Ubiquinone/administration & dosage ; Ubiquinone/analogs & derivatives
    Chemische Substanzen Anticholesteremic Agents ; Blood Glucose ; Cholesterol, HDL ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Triglycerides ; Ubiquinone (1339-63-5) ; Lovastatin (9LHU78OQFD) ; coenzyme Q10 (EJ27X76M46)
    Sprache Englisch
    Erscheinungsdatum 2018-06-19
    Erscheinungsland France
    Dokumenttyp Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 392415-4
    ISSN 1950-6007 ; 0753-3322 ; 0300-0893
    ISSN (online) 1950-6007
    ISSN 0753-3322 ; 0300-0893
    DOI 10.1016/j.biopha.2018.06.076
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ud II Zs.198: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Artikel ; Online: Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice.

    Mazza, Alberto / Lenti, Salvatore / Schiavon, Laura / Sacco, Antonella Paola / Dell'Avvocata, Fabio / Rigatelli, Gianluca / Ramazzina, Emilio

    Advances in therapy

    2017  Band 34, Heft 4, Seite(n) 975–985

    Abstract: Introduction: Blood pressure (BP) control is the main clinical goal in the management of hypertensive patients; however, BP in most of these patients remains uncontrolled, despite the widespread availability of antihypertensive drugs as free-combination ...

    Abstract Introduction: Blood pressure (BP) control is the main clinical goal in the management of hypertensive patients; however, BP in most of these patients remains uncontrolled, despite the widespread availability of antihypertensive drugs as free-combination therapy. This study compared the efficacy of a fixed-dose triple combination (FDTC) of antihypertensive drugs with that of a free combination of three antihypertensives in patients with uncontrolled hypertension.
    Methods: Ninety-two patients (mean age 60.8 ± 12.1, 58.0% male) with uncontrolled essential hypertension (office systolic BP ≥ 140 or diastolic BP ≥ 90 mmHg) previously treated with a renin-angiotensin-aldosterone system (RAAS) inhibitor plus hydrochlorothiazide were switched to once-daily FDTC therapy with perindopril/indapamide/amlodipine (5-10/1.25-2.5/5-10 mg). Patients were age- and sex-matched with a control group of hypertensive patients receiving free-combination therapy with three drugs including a RAAS inhibitor, a diuretic, and a calcium channel blocker. Office BP and 24-h ambulatory BP monitoring (ABPM) were evaluated at baseline and after 1 and 4 months.
    Results: Significant reductions in ambulatory 24-h, daytime, and nighttime systolic BP, and pulse pressure (PP) were found in the FDTC group relative to reductions seen with free-combination therapy, after the first month only of follow-up. Target BP values (mean 24-h ambulatory systolic/diastolic BP < 130/80 mmHg) were reached by more recipients of FDTC than free-combination therapy (64.8% vs. 46.9%, p < 0.05) at month 4 of follow-up, despite reductions in 24-h ABPM values from baseline being similar in both groups at this time point.
    Conclusion: FDTC of perindopril/indapamide/amlodipine was effective at reducing SBP and PP in previously treated patients with uncontrolled hypertension, and well tolerated, providing support for clinicians in choosing a fixed-dose triple combination over the free-combination of a RAAS inhibitor, a diuretic, and a calcium antagonist.
    Mesh-Begriff(e) Aged ; Amlodipine/administration & dosage ; Amlodipine/adverse effects ; Amlodipine/therapeutic use ; Antihypertensive Agents/administration & dosage ; Antihypertensive Agents/adverse effects ; Antihypertensive Agents/therapeutic use ; Blood Pressure/drug effects ; Blood Pressure Monitoring, Ambulatory ; Calcium Channel Blockers/therapeutic use ; Diuretics/therapeutic use ; Drug Combinations ; Female ; Humans ; Hypertension/drug therapy ; Indapamide/administration & dosage ; Indapamide/adverse effects ; Indapamide/therapeutic use ; Male ; Medication Adherence ; Middle Aged ; Perindopril/administration & dosage ; Perindopril/adverse effects ; Perindopril/therapeutic use
    Chemische Substanzen Antihypertensive Agents ; Calcium Channel Blockers ; Diuretics ; Drug Combinations ; Amlodipine (1J444QC288) ; Indapamide (F089I0511L) ; Perindopril (Y5GMK36KGY)
    Sprache Englisch
    Erscheinungsdatum 2017-03-15
    Erscheinungsland United States
    Dokumenttyp Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632651-1
    ISSN 1865-8652 ; 0741-238X
    ISSN (online) 1865-8652
    ISSN 0741-238X
    DOI 10.1007/s12325-017-0511-1
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2101: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  9. Artikel ; Online: Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population.

    Mazza, Alberto / Lenti, Salvatore / Schiavon, Laura / Monte, Alvise Del / Townsend, Danyelle M / Ramazzina, Emilio / Rubello, Domenico / Casiglia, Edoardo

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    2017  Band 86, Seite(n) 590–594

    Abstract: Objective: In clinical practice, patient characteristics predicting resistant hypertension (RH) include higher blood pressure levels, left ventricular hypertrophy, older age, obesity, chronic kidney disease and diabetes. On the contrary little is known ... ...

    Abstract Objective: In clinical practice, patient characteristics predicting resistant hypertension (RH) include higher blood pressure levels, left ventricular hypertrophy, older age, obesity, chronic kidney disease and diabetes. On the contrary little is known about the role of serum uric acid (SUA) as a risk factor for RH in subjects from general population.
    Material and methods: 580 elderly subjects aged ≥65 years were enrolled in the Risk Of Vascular complications Impact of Genetics in Old people (ROVIGO) study. RH was defined as the failure to maintain blood pressure values below 140mmHg (systolic) and 90mmHg (diastolic) despite therapeutic interventions that include appropriate lifestyle measures plus adherence to treatment with full doses of at least three antihypertensive drugs, including a diuretic. RH was confirmed using 24-h ambulatory blood pressure measurement. Hyperuricemic was defined as the subjects having SUA ≥6.8mg/dl or taking uricosuric drugs. Gender-specific odds ratio (OR) for RH was calculated by logistic regression analysis.
    Results: The prevalence of RH was 5.7% in the cohort and was higher in women (8.3%) than in men (3.0%, p<0.05). Independent of chronic kidney disease (OR 3.89, 95% confidence interval 1.49-10.1), hyperuricemia predicted resistant hypertension in women (odds ratio 3.11, 95% confidence intervals 1.06-9.1, p=0.03) but not in men.
    Conclusions: In elderly women from the general population, an SUA value of ≥6.8mg/dl triples the risk of RH. SUA assessment should be recommended to better define the pattern of risk associated with RH.
    Mesh-Begriff(e) Aged ; Antihypertensive Agents/pharmacology ; Blood Pressure/drug effects ; Blood Pressure/physiology ; Blood Pressure Monitoring, Ambulatory/methods ; Cross-Sectional Studies ; Female ; Humans ; Hypertension/blood ; Hypertension/drug therapy ; Hypertension/etiology ; Hyperuricemia/blood ; Hyperuricemia/complications ; Longitudinal Studies ; Male ; Prevalence ; Risk Factors ; Sex Factors ; Uric Acid/blood
    Chemische Substanzen Antihypertensive Agents ; Uric Acid (268B43MJ25)
    Sprache Englisch
    Erscheinungsdatum 2017-02
    Erscheinungsland France
    Dokumenttyp Journal Article
    ZDB-ID 392415-4
    ISSN 1950-6007 ; 0753-3322 ; 0300-0893
    ISSN (online) 1950-6007
    ISSN 0753-3322 ; 0300-0893
    DOI 10.1016/j.biopha.2016.11.104
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ud II Zs.198: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  10. Artikel ; Online: Nutraceuticals for Serum Lipid and Blood Pressure Control in Hypertensive and Hypercholesterolemic Subjects at Low Cardiovascular Risk.

    Mazza, Alberto / Lenti, Salvatore / Schiavon, Laura / Zuin, Marco / D'Avino, Maria / Ramazzina, Emilio / Casiglia, Edoardo

    Advances in therapy

    2015  Band 32, Heft 7, Seite(n) 680–690

    Abstract: Introduction: Primary cardiovascular (CV) prevention may be achieved by lifestyle/nutrition changes, although a relevant role is now emerging for specific, functional foods and nutraceutical compounds (NCs). The aim of this study was to investigate the ... ...

    Abstract Introduction: Primary cardiovascular (CV) prevention may be achieved by lifestyle/nutrition changes, although a relevant role is now emerging for specific, functional foods and nutraceutical compounds (NCs). The aim of this study was to investigate the efficacy and safety of NCs in lowering blood pressure (BP) and improving lipid profile, when added to diet and lifestyle management versus diet alone in a group of patients with hypertension (HT) and hypercholesterolemia (HCh) with low CV risk.
    Methods: Sixty-six patients with HT and HCh with grade 1 essential HT (mean age 56.0 ± 4.6 years) without history of CV diseases or organ damage were analyzed. These subjects were started on one tablet of an NC-containing red yeast rice, policosanol, berberine, folic acid and coenzyme Q10 once daily for 6 months and were age and gender matched with subjects following a diet program. Differences in clinic BP, 24-h ambulatory BP (24 h-ABPM), serum total cholesterol, low-density and high-density lipoprotein cholesterol (LDL-C and HDL-C) and triglyceride values were compared by analysis of variance.
    Results: In the treatment group, a significant reduction of systolic 24 h-ABPM (141.6 ± 6.4 vs. 136.2 ± 4.8 mmHg; p < 0.05) and pulse pressure 24 h-ABPM (52.6 ± 7.2 vs. 47.3 ± 5.4 mmHg; p < 0.05) was found at the end of follow-up. A reduction of total cholesterol (-19.2%), LDL-C (-17.4%) and triglycerides (-16.3%) was observed (p < 0.001 for all); HDL-C remained unchanged. No difference was found in the control group.
    Conclusions: The tested NCs was found to be safe, well tolerated and effective in reducing mean 24-h systolic and 24-h pulse pressure and in improving lipid pattern.
    Mesh-Begriff(e) Berberine/therapeutic use ; Biological Products/therapeutic use ; Blood Pressure/drug effects ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/epidemiology ; Diet ; Dietary Supplements ; Fatty Alcohols/therapeutic use ; Female ; Folic Acid/therapeutic use ; Health Behavior ; Humans ; Hypercholesterolemia/drug therapy ; Hypertension/drug therapy ; Life Style ; Lipids/blood ; Male ; Middle Aged ; Risk Factors ; Ubiquinone/analogs & derivatives ; Ubiquinone/therapeutic use
    Chemische Substanzen Biological Products ; Fatty Alcohols ; Lipids ; red yeast rice ; Berberine (0I8Y3P32UF) ; Ubiquinone (1339-63-5) ; policosanol (142583-61-7) ; Folic Acid (935E97BOY8) ; coenzyme Q10 (EJ27X76M46)
    Sprache Englisch
    Erscheinungsdatum 2015-07
    Erscheinungsland United States
    Dokumenttyp Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632651-1
    ISSN 1865-8652 ; 0741-238X
    ISSN (online) 1865-8652
    ISSN 0741-238X
    DOI 10.1007/s12325-015-0229-x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2101: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang